<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02687152</url>
  </required_header>
  <id_info>
    <org_study_id>Micro Arginase</org_study_id>
    <nct_id>NCT02687152</nct_id>
  </id_info>
  <brief_title>Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes</brief_title>
  <official_title>Effect of Arginase Inhibition on Microvascular Endothelial Function in Patients With Type 2 Diabetes and Microvascular Dysfunction.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project is designed to test the hypothesis that arginase contributes to&#xD;
      microvascular endothelial dysfunction in patients with type 2 diabetes and microvascular&#xD;
      complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      The development of microvascular complications in diabetes is a complex process, in which&#xD;
      endothelial dysfunction is of importance. Emerging evidence suggests that arginase is a key&#xD;
      mediator of endothelial dysfunction in type 2 diabetes mellitus (T2DM) by reciprocally&#xD;
      regulating nitric oxide bioavailability. The aim of this study was to test the hypothesis&#xD;
      that arginase activity is increased and that arginase contributes to microvascular&#xD;
      endothelial function in patients with T2DM and microvascular dysfunction.&#xD;
&#xD;
      Method&#xD;
&#xD;
      Microvascular endothelium-dependent and -independent vasodilatation are investigated in&#xD;
      patients with T2DM (n =12) and healthy age-matched control subjects (n =12) with&#xD;
      laser-Doppler flowmetry during iontophoretic application of acetylcholine and sodium&#xD;
      nitroprusside, respectively, before and after intra-arterial administration of the arginase&#xD;
      inhibitor N-hydroxy-nor-L-arginine (0.1 mg/min) for 120 min.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in cutaneous microvascular endothelial function</measure>
    <time_frame>2 hours</time_frame>
    <description>Laser Doppler flow rate</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arginase inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-hydroxyl-nor-L-arginine, i.a. 0.1 mg/min for 120 min</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>N-hydroxy-nor-L-arginine</intervention_name>
    <arm_group_label>Arginase inhibition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of type 2 diabetes mellitus and microvascular dysfunction defined&#xD;
             as microalbuminuria &gt; 3.0 mg/mmol or presence of retinopathy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Myocardial infarction or unstable angina within the last three months,&#xD;
&#xD;
          -  Changed dose of any vasodilator drug during the preceding six weeks,&#xD;
&#xD;
          -  Ongoing treatment with warfarin&#xD;
&#xD;
          -  Concomitant disease that may have interfered with the possibility for the patients to&#xD;
             comply with or complete the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Pernow, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2016</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>John Pernow</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

